{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:10:56Z","timestamp":1794276656128,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["145101"],"award-info":[{"award-number":["145101"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ebiom.2025.106055","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:12:50Z","timestamp":1764943970000},"page":"106055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-7878","authenticated-orcid":false,"given":"Ajith","family":"Sivadasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fernyhough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Calcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Frizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Breiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Zochodne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubin","family":"Punthakee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ebiom.2025.106055_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2337\/dci18-0012","article-title":"The cost of diabetes Care-An elephant in the room","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ebiom.2025.106055_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106055_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-020-01259-2","article-title":"Treating pain in diabetic neuropathy: current and developmental drugs","volume":"80","author":"Alam","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106055_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diabres.2015.04.031","article-title":"Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature","volume":"109","author":"Alleman","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106055_bib6","first-page":"CD007543","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"6","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.05.005","article-title":"Diabetic neuropathy: mechanisms to management","volume":"120","author":"Edwards","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106055_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1172\/JCI88321","article-title":"Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy","volume":"127","author":"Calcutt","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2025.106055_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.irn.2016.02.004","article-title":"Can diabetic neuropathy be modeled in vitro?","volume":"127","author":"Gardiner","year":"2016","journal-title":"Int Rev Neurobiol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106055_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11892-015-0671-9","article-title":"Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events","volume":"15","author":"Fernyhough","year":"2015","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ebiom.2025.106055_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fnins.2018.00402","article-title":"Muscarinic acetylcholine type 1 receptor activity constrains neurite outgrowth by inhibiting microtubule polymerization and mitochondrial trafficking in adult sensory neurons","volume":"12","author":"Sabbir","year":"2018","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.120.265447","article-title":"Topical delivery of muscarinic receptor antagonists prevents and reverses peripheral neuropathy in female diabetic mice","volume":"374","author":"Jolivalt","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ebiom.2025.106055_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.663373","article-title":"Prevention of HIV-1 TAT protein-induced peripheral neuropathy and mitochondrial disruption by the antimuscarinic pirenzepine","volume":"12","author":"Han","year":"2021","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106055_bib14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s12035-020-01900-x","article-title":"Muscarinic toxin 7 signals via Ca2+\/Calmodulin-Dependent protein kinase kinase \u03b2 to augment mitochondrial function and prevent neurodegeneration","volume":"57","author":"Saleh","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106055_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-1759(86)90197-3","article-title":"Automated monoclonal radioimmunoassays for pirenzepine, a selective muscarinic receptor antagonist, in plasma and urine","volume":"93","author":"Tanswell","year":"1984","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ebiom.2025.106055_bib16","first-page":"1","article-title":"The pharmacokinetic profile of pirenzepine","volume":"57","author":"Hammer","year":"1979","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106055_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaapos.2007.10.014","article-title":"Two-year multicenter, randomized, double-masked, placebo- controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia","volume":"12","author":"Siatkowski","year":"2008","journal-title":"J AAPOS"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib18","article-title":"Interventions to slow progression of myopia in children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106055_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-198530020-00001","article-title":"Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases","volume":"30","author":"Carmine","year":"1985","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106055_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1358\/dot.2010.46.6.1487750","article-title":"Oxybutynin topical and transdermal formulations: an update","volume":"46","author":"Staskin","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ebiom.2025.106055_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106055_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cpmo.11","article-title":"Peripheral neuropathy in mouse models of diabetes","volume":"6","author":"Jolivalt","year":"2016","journal-title":"Curr Protoc Mouse Biol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106055_bib23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/dmrr.1226","article-title":"Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity","volume":"27","author":"Dyck","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106055_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1468-1331.2010.03023.x","volume":"17","author":"Lauria","year":"2010","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106055_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106055_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/193229681100500326","article-title":"Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate","volume":"5","author":"Boyd","year":"2011","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70011","article-title":"Dapagliflozin for small nerve fibre regeneration in diabetic peripheral neuropathy: a randomised controlled study (DINE)","volume":"30","author":"Adhikari","year":"2025","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106055_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00401-024-02710-4","article-title":"A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin","volume":"147","author":"Casselini","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106055_bib29","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00125-013-2942-9","article-title":"Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial","volume":"56","author":"Pop-Busui","year":"2013","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106055_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jdiacomp.2015.07.013","article-title":"Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study","volume":"29","author":"Jaiswal","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106055_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12457","article-title":"Phase 2a randomized controlled study investigating the safety and efficacy of PDA-002 in diabetic peripheral neuropathy","volume":"26","author":"Gibbons","year":"2021","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106055_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2522\/ptj.20140108","article-title":"Safety of aerobic exercise in people with diabetic peripheral neuropathy: single-group clinical trial","volume":"95","author":"Kluding","year":"2015","journal-title":"Phys Ther"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106055_bib33","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00125-019-4897-y","article-title":"Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation","volume":"62","author":"Azmi","year":"2019","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106055_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106055_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","article-title":"Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study","volume":"181","author":"Staskin","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ebiom.2025.106055_bib36","first-page":"35","article-title":"Cerebro-spinal fluid concentrations of pirenzepine after therapeutic dosage","volume":"66","author":"Jaup","year":"1980","journal-title":"Scand J Gastroenterol Suppl"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425004992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:39:07Z","timestamp":1778873947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425004992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S2352396425004992"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106055","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106055"}}